Stopoutsin (Stoptussin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsppills
Composition:

1 tablet contains:

active substances: butamirate citrate 4.0 mg; guaifenesin 100.0 mg;

Excipients: silicon dioxide colloid 1.0 mg, mannitol 60.0 mg, microcrystalline cellulose 60.0 mg, glyceryl tribehenate 1.0 mg, magnesium stearate 4.0 mg.

Description:

Ploskotsilindricheskie tablets white or almost white, with a facet and separation risk.

Pharmacotherapeutic group:antitussive drug combined (antitussive drug of central action + expectorant)
ATX: & nbsp
  • Antitussive drugs in combination with expectorants
    • Pharmacodynamics:

    Combined drug, which has antitussive and expectorant effect.

    Butamate has a peripheral local anesthetic effect on the sensitive nerve endings of the bronchial mucosa, which provides an antitussive effect.

    Guaifenesin increases the secretion of bronchial glands and reduces the viscosity of mucus. Increased secretion is caused as a direct effect on the bronchial glands by stimulating the secretion of secretions from the bronchial glands and removing acidic glycoproteins from acinar cells and reflexively when irritation of the afferent parasympathetic fibers of the gastric mucosa occurs and the respiratory center is depressed. Increased tone N. vagus stimulates the production of bronchial secretions. Slime produced by the bronchial glands enhances the activity of the ciliary epithelium, which facilitates the evacuation of mucus from the bronchi and its coughing.

    Pharmacokinetics:

    Ingestion butamate quickly and completely absorbed. The connection with plasma proteins is 94%. It is metabolized with the formation of 2 metabolites, which also have antitussive action. Metabolites are excreted mainly (90%) by the kidneys and only a small part through the intestine. The half-life (T1/2) - 6 hours.

    Guaifenesin when ingested quickly absorbed from the gastrointestinal tract. The connection with plasma proteins is insignificant. Guaifenesin rapidly metabolized, with the formation of inactive metabolites, which are excreted by the kidneys. T1/2 - 1 hour.

    Indications:

    Dry and irritating cough of various etiologies (including infectious and inflammatory diseases of the upper and lower respiratory tract).

    Contraindications:

    Hypersensitivity to the constituent components; myasthenia gravis; children's age till 12 years; I trimester of pregnancy; the period of breastfeeding.

    Pregnancy and lactation:

    The drug Stoptussin should not be used in the first trimester of pregnancy. If it is necessary to use it in the II and III trimester of pregnancy, you should make sure that the prospective benefit to the mother is greater than the potential risk to the fetus.

    There is no reliable information on the penetration of butamirate and guaifenesin into breast milk. It is necessary to stop breastfeeding for the period of use of the drug Stoptopsin.

    Dosing and Administration:

    Inside, after eating, without chewing, washing with liquid (water, tea, fruit juice, etc.). The dose depends on the weight of the patient's body.

    Adults and children over 12 years of age with weight:

    - less than 50 kg: 1/2 tablet 4 times a day;

    - from 50 to 70 kg: 1 tablet 3 times a day;

    - 70 to 90 kg: 1 each1/2 tablet 3 times a day;

    - more than 90 kg: 1 each1/2 tablet 4 times a day.

    The interval between doses should be 4-6 hours.

    Side effects:

    When the recommended dosage regimen is observed, patients usually tolerate the drug well. There may be nausea, vomiting, diarrhea, decreased appetite, stomach pain, dizziness, headache, drowsiness, urticaria, and skin rash. These effects appear in about 1 patient and usually go without reducing the dose.

    The frequency of adverse reactions listed below was determined according to the following criteria: very often (not less than 1/10), often (more than 1/100, less than 1/10); infrequently (more than 1/1000, less than 1/100); rarely (more than 1/10000, less than 1/1000); very rarely (less than 1/10000), including individual messages.

    From the central nervous system: often a headache.

    From the side of the organ of hearing and balance: often - dizziness.

    On the part of the digestive system: often - nausea, anorexia, abdominal pain, vomiting, diarrhea; very rarely - a bitter taste in the mouth, heartburn, a feeling of heaviness in the epigastrium.

    On the part of the respiratory system: very rarely - dyspnea.

    From the cardiovascular system: rarely - chest pain, very rarely - tachycardia, palpitation.

    From the skin and subcutaneous fat: very rarely - itching, exanthema, urticaria, "hot flashes".

    Other: very rarely - pain around the eyes.

    Overdose:

    Symptoms: signs of toxic effects of guaifenesin predominate: drowsiness, muscle weakness, nausea and vomiting, urolithiasis.

    Treatment: it is necessary to see a doctor. Guaifenesin does not have a specific antidote. Assign gastric lavage, reception of activated charcoal, symptomatic therapy (support of cardiovascular, respiratory and renal functions, electrolyte balance).

    Interaction:

    Guaifenesin enhances the analgesic effect of paracetamol and acetylsalicylic acid; enhances the effect of alcohol, sedatives, hypnotics and general anesthetics on the central nervous system; enhances the effect of muscle relaxants.

    When determining the concentration of vanillylmindal and 5-hydroxyindoleacetic acid using nitrosonaphthol as a reagent, false-positive results can be obtained. Therefore, treatment with guaifenesin should be stopped 48 hours before urine collection for this analysis.

    Special instructions:

    If symptoms persist, consider changing the treatment.

    The drug should not be administered with productive cough to patients suffering from prolonged or chronic coughing (including those caused by smoking), bronchitis or emphysema of the lungs.

    Effect on the ability to drive transp. cf. and fur:

    The drug Stoptussin can have an adverse effect on the ability to drive vehicles and to engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions due to the fact that it can cause dizziness and other side effects.

    Form release / dosage:Tablets, 4 mg + 100 mg.
    Packaging:

    For 10 tablets in blisters of aluminum foil and PVC film.

    Two blisters together with instructions for use are placed in a cardboard box.
    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.
    Shelf life:

    5 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:П N015070 / 01
    Date of registration:13.04.2010 / 11.12.2012
    The owner of the registration certificate:Teva Pharmaceutical Enterprises Co., Ltd.Teva Pharmaceutical Enterprises Co., Ltd. Israel
    Manufacturer: & nbsp
    Representation: & nbspTeva Teva Israel
    Information update date: & nbsp20.03.2016
    Illustrated instructions
      Instructions
      Up